Plasma LncRNA FEZF1-AS1 As A Potential Biomarker For Diagnosis Of Non-small-cell Lung Carcinoma

Objective: Diagnosis of numerous cancers has been closely linked to the expression of certain long non-coding RNAs(lnc RNA).This study aimed to evaluate levels of plasma FEZF1-AS1 relative to non-small-cell lung carcinoma(NSCLC)diagnosis.Methods:1 The level of FEZF1-AS1 in the blood plasma of 126 NSCLC patients and 62 healthy controls was examined by q RT-PCR.2 The association between plasma FEZF1-AS1 and clinicopathological features of NSCLC were analyzed by Pearson Chisquared test and Mann–Whitney U test.3 The diagnostic values of linear predictor,or logit,resulting from the multivariable model were calculated using the ROC curves.4 The risk of NSCLC was analyzed by multivariate analysis using non-conditional logistic regression analysis.Results: 1 Plasma FEZF1-AS1 of the NSCLC group was increased compared with that in the control group(P<0.0001),plasma FEZF1-AS1 expression was significantly upregulated in advanced clinical stage,AD and SCC group compared with that in the control group(P<0.0001).2 Plasma FEZF1-AS1 could distinguish patients with NSCLC from healthy individuals via the area under the ROC curve(AUC)of 0.855(95% CI= 0.800–0.909;P=0.000).3 FEZF1-AS1 combined with neuron-specific enolase(NSE)increased the AUC to 0.932(95% CI= 0.897–0.968;P=0.018).4 A high expression level of plasma FEZF1-AS1 was associated with some clinical features of NSCLC.5 Increased expression of FEZF1-AS1 greatly improved the risk of NSCLC(adjusted OR= 2.42;95% CI= 1.23–4.76).A significant concentration–dependent relationship was noted between risk of NSCLC and higher FEZF1-AS1 expression(P for trend<0.001).Conclusions: Plasma FEZF1-AS1 could potentially be used as a potential biomarker for NSCLC diagnosis.Plasma FEZF1-AS1 expression was significantly upregulated in patient groups with positive distant metastasis,positive lymph node metastasis,advanced clinical stage and tumor diameter over 3cm.